Nadroparin for the Initial Treatment of Pulmonary Thromboembolism
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Low-molecular-weight heparin (LWMH) appears to be at least as effective and safe as standard,
unfractionated heparin (UFH)for the treatment of patients with deep vein thrombosis(DVT) and
may also be so in patients with pulmonary thromboembolism (PTE). Only limited data are
available on the evaluation of body weight adjusted LWMH and standard UFH for the initial
treatment of PTE in Chinese population. The aim of this study is to determine whether body
weight-adjusted, subcutaneous Nadroparin is as effective and safe as UFH for treatment of
patients with objectively documented PTE.